RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Seelos Therapeutics Stock

Seelos Therapeutics Net Income 2024

Seelos Therapeutics Net Income

-9.33 M USD

Ticker

SEEL

ISIN

US81577F1093

WKN

A2PDK8

In 2024, Seelos Therapeutics's profit amounted to -9.33 M USD, a -75.38% increase from the -37.88 M USD profit recorded in the previous year.

The Seelos Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2028e-
2027e-
2026e-3,510.85
2025e-2,278.27
2024e-9,326.68
2023-37,882
2022-73,534
2021-66,048
2020-19,101
2019-51,255
2018-3,475
2017321
2016-7,433
2015-19,023
2014-21,786
2013-16,938
2012-31,771
2011-18,117
2010-29,508
2009-32,042.6
2008-5,172
2007-8,787
2006-8,109
2005-16,550
2004-17,023

Seelos Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Seelos Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Seelos Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Seelos Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Seelos Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Seelos Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Seelos Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Seelos Therapeutics’s growth potential.

Seelos Therapeutics Revenue, EBIT and net profit per share

DateSeelos Therapeutics RevenueSeelos Therapeutics EBITSeelos Therapeutics Net Income
2028e370.24 M undefined0 undefined0 undefined
2027e258.92 M undefined6.02 M undefined0 undefined
2026e206.96 M undefined-31.82 M undefined-3.51 M undefined
2025e28.97 M undefined-63.55 M undefined-2.28 M undefined
2024e306,000 undefined-36.62 M undefined-9.33 M undefined
20232.2 M undefined-40.5 M undefined-37.88 M undefined
20220 undefined-70.92 M undefined-73.53 M undefined
20210 undefined-61.67 M undefined-66.05 M undefined
20200 undefined-18.76 M undefined-19.1 M undefined
2019375,000 undefined-29.75 M undefined-51.26 M undefined
20180 undefined-3.18 M undefined-3.48 M undefined
20170 undefined-10.67 M undefined321,000 undefined
20160 undefined-13.66 M undefined-7.43 M undefined
20154.84 M undefined-21.25 M undefined-19.02 M undefined
20149.26 M undefined-24.37 M undefined-21.79 M undefined
20132.51 M undefined-18.79 M undefined-16.94 M undefined
20127.95 M undefined-14.21 M undefined-31.77 M undefined
20113.6 M undefined-15.53 M undefined-18.12 M undefined
20104.97 M undefined-11.23 M undefined-29.51 M undefined
20092.97 M undefined-3.27 M undefined-32.04 M undefined
20085.96 M undefined-4.27 M undefined-5.17 M undefined
20071.27 M undefined-9.39 M undefined-8.79 M undefined
20061.87 M undefined-9.13 M undefined-8.11 M undefined
20052.4 M undefined-15.7 M undefined-16.55 M undefined
2004360,000 undefined-17.3 M undefined-17.02 M undefined

Seelos Therapeutics stock margins

The Seelos Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Seelos Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Seelos Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Seelos Therapeutics's sales revenue. A higher gross margin percentage indicates that the Seelos Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Seelos Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Seelos Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Seelos Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Seelos Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Seelos Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Seelos Therapeutics Margin History

Seelos Therapeutics Gross marginSeelos Therapeutics Profit marginSeelos Therapeutics EBIT marginSeelos Therapeutics Profit margin
2028e80.95 %0 %0 %
2027e80.95 %2.32 %0 %
2026e80.95 %-15.38 %-1.7 %
2025e80.95 %-219.37 %-7.86 %
2024e80.95 %-11,966.67 %-3,047.93 %
202380.95 %-1,838.36 %-1,719.56 %
202280.95 %0 %0 %
202180.95 %0 %0 %
202080.95 %0 %0 %
201980.95 %-7,932.53 %-13,668 %
201880.95 %0 %0 %
201780.95 %0 %0 %
201680.95 %0 %0 %
201580.95 %-439.1 %-393.12 %
201490.09 %-263.15 %-235.3 %
2013-4.78 %-748.5 %-674.55 %
201246.63 %-178.8 %-399.89 %
201148.43 %-430.95 %-502.83 %
201020.71 %-225.88 %-593.36 %
200995.69 %-109.93 %-1,077.53 %
2008100 %-71.68 %-86.82 %
2007100 %-739.13 %-691.89 %
200680.95 %-488.97 %-434.33 %
200580.95 %-654.48 %-689.87 %
2004100 %-4,806.67 %-4,728.61 %

Seelos Therapeutics Aktienanalyse

What does Seelos Therapeutics do?

Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. The company was founded in 2016 by Raj Mehra and is headquartered in New York City. Seelos Therapeutics Inc specializes in the development of therapeutics for neurological and psychiatric disorders, with a focus on treating patients with severe, chronic, or life-threatening conditions. The company has developed an innovative business model based on collaboration with various institutions, organizations, and companies. The company is divided into several divisions, including clinical development, product development, technology development, and strategic partnerships. Each division focuses on specific aspects of therapy development and contributes to Seelos' ability to develop innovative and effective therapeutics for its patients. In the clinical development division, Seelos Therapeutics Inc focuses on conducting clinical trials to assess the efficacy and safety of its therapeutics. The company works closely with various academic institutions and clinics to conduct its clinical studies and ensure they adhere to the highest scientific standards. The product development division is responsible for the development of Seelos' actual therapeutics. It encompasses research, development, manufacturing, and quality assurance of the company's products. Seelos emphasizes rigorous quality and safety management to ensure its products meet the highest standards. In the technology development division, Seelos focuses on developing innovative technologies for therapy development. In collaboration with various institutions and companies, the company invests in the development of new technologies to improve its therapeutics and optimize patient care. A crucial aspect of Seelos' business model is collaboration with other companies and institutions. The company has formed strategic partnerships with various institutions and companies in the biotechnology and pharmaceutical fields. This allows Seelos to leverage the expertise and resources of other companies and expedite the development of its therapeutics. Seelos' flagship product is SLS-002, a novel rapid-onset nasal ketamine for the treatment of suicidality in patients with depression and bipolar disorder. SLS-002 has shown promising results in clinical trials and is currently in Phase 2b of clinical development. Seelos is also working on the development of therapeutics for other neurological and psychiatric disorders, such as Huntington's disease, neuropathic pain, and Amyotrophic Lateral Sclerosis (ALS). Overall, Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. Through its innovative business model and collaboration with other companies and institutions, Seelos aims to expedite the development of its therapeutics and improve the lives of patients with severe, chronic, or life-threatening conditions. Seelos Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Seelos Therapeutics's Profit Margins

The profit margins of Seelos Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Seelos Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Seelos Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Seelos Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Seelos Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Seelos Therapeutics stock

How much profit has Seelos Therapeutics made this year?

Seelos Therapeutics has made -9.33 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -75.38% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Seelos Therapeutics publish its earnings?

Seelos Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Seelos Therapeutics?

The profits of Seelos Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Seelos Therapeutics?

You can learn more about the earnings of Seelos Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Seelos Therapeutics pay?

Over the past 12 months, Seelos Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seelos Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seelos Therapeutics?

The current dividend yield of Seelos Therapeutics is .

When does Seelos Therapeutics pay dividends?

Seelos Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seelos Therapeutics?

Seelos Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seelos Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seelos Therapeutics located?

Seelos Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seelos Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seelos Therapeutics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Seelos Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Seelos Therapeutics in the year 2023?

In the year 2023, Seelos Therapeutics distributed 0 USD as dividends.

In which currency does Seelos Therapeutics pay out the dividend?

The dividends of Seelos Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Seelos Therapeutics

Our stock analysis for Seelos Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seelos Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.